Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism

Journal of Medicinal Chemistry

Volumn 51, Issue 21, 2008, Pages 6970-6979

  Ortar, Giorgio ^a   Bisogno, Tiziana ^b   Ligresti, Alessia ^b   Morera, Enrico ^a   Nalli, Marianna ^a   Di Marzo, Vincenzo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; LIPOPROTEIN LIPASE; N ACETYL ISOLEUCINE 1 [3 HEXYL 4 OXO 2 OXETANYL]METHYL]DODECYL ESTER; N ACETYL VALINE 1 [[3 HEXYL 4 OXO 2 OXETANYL]METHYL]DODECYL ESTER; N FORMYL ALANINE 1 [3 HEXYL 4 OXO 2 OXETANYL]METHYL]DODECYL ESTER; N FORMYL ISOLEUCINE 1 [[3 HEXYL 4 OXO 2 OXETANYL]METHYL]DODECYL ESTER; N FORMYL VALINE 1 [[3 HEXYL 4 OXO 2 OXETANYL]METHYL]DODECYL ESTER; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; NONHUMAN;

ANIMALS; ARACHIDONIC ACIDS; CELL LINE, TUMOR; ENDOCANNABINOIDS; GLYCERIDES; INHIBITORY CONCENTRATION 50; LACTONES; MICE; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 56249108088     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800978m     Document Type: Article

References (60)

1. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
2. (a) Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50, 83-90.
3. (b) Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K. 2-Arachidonoylglycerol, a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
4. Sugiura, T.; Kobayashi, Y.; Oka, S.; Waku, K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 173-192.
5. Di Marzo, V.; De Petrocellis, L.; Fezza, F.; Ligresti, A.; Bisogno, T. Anandamide receptors. Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66, 377-391.
6. (a) Basavarajappa, B. S. Critical enzymes involved in endocannabinoid metabolism. Protein Peptide Lett. 2007, 14, 237-246.
7. (b) Ligresti, A.; Cascio, M. G.; Di Marzo, V. Endocannabinoid metabolic pathways and enzymes. CNS Neurol. Disord.: Drug Targets 2005, 4, 615-623.
8. (c) Lambert, D. M.; Fowler, C. J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 2005, 48, 5059-5087.
9. (d) Bisogno, T.; Ligresti, A.; Di Marzo, V. The endocannabinoid signalling system: biochemical aspects. Pharmacol., Biochem. Behav. 2005, 81, 224-238.
10. (e) De Petrocellis, L.; Cascio, M. G.; Di Marzo, V. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 2004, 141, 765-774.
11. Bisogno, T.; Howell, F.; Williams, G.; Minassi, A.; Cascio, M. G.; Ligresti, A.; Matias, I.; Schiano-Moriello, A.; Paul, P.; Williams, E.-J.; Gangadharan, U.; Hobbs, C.; Di Marzo, V.; Doherty, P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell. Biol. 2003, 163, 463-468.
12. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce. Nat. Rev. Drug Discovery 2008, 7, 438-455.
13. Ghafouri, N.; Tiger, G.; Razdan, R. K.; Mahadevan, A.; Pertwee, R. G.; Martin, B. R.; Fowler, C. J. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br. J. Pharmacol. 2004, 143, 774-784.
14. Makara, J. K.; Mor, M.; Fegley, D.; Szabo, S. I.; Kathuria, S.; Astarita, G.; Durand, A.; Tontini, A.; Tarzia, G.; Rivara, S.; Freund, T. F.; Piomelli, D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat. Neurosci. 2005, 8, 1139-1141.
15. Bisogno, T.; Cascio, M. G.; Saha, B.; Mahadevan, A.; Urbani, P.; Minassi, A.; Appendino, G.; Saturnino, C.; Martin, B.; Razdan, R.; Di Marzo, V. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim. Biophys. Acta 2006, 1761, 205-212.
16. (a) Weibel, E. K.; Hadvary, P.; Hochuli, E.; Kupfer, E.; Lengsfeld, H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation, and biological activity. J. Antibiot. 1987, 40, 1081-1085.
17. (b) Hochuli, E.; Kupfer, E.; Maurer, R.; Meister, W.; Mercadal, Y.; Schmidt, K. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation. J. Antibiot. 1987, 40, 1086-1091.
18. (a) Guerciolini, R. Mode of action of Orlistat. Int. J. Obes. 1997, 21, S12-S23.
19. (b) Lookene, A.; Skottova, N.; Olivecrona, G. Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Eur. J. Biochem. 1994, 222, 395-103.
20. (c) Stalder, H.; Oesterhelt, G. Tetrahydrolipstatin: degradation products produced by human carboxyl-ester lipase. Helv. Chim. Acta 1992, 75, 1593-1603.
21. (d) Hadvary, P.; Sidler, W.; Meister, W.; Vetter, W.; Wolfer, H. The lipase inibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J. Biol. Chem. 1991, 266, 2021-2027.
22. (e) Borgström, B. Mode of action of tetrahydroplipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim. Biophys. Acta 1988, 962, 308-316.
23. (a) Hashimotodani, Y.; Ohno-Shosaku, T.; Maejima, T.; Fukami, K.; Kano, M. Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocannabinoid release. Neuropharmacology 2008, 54, 58-67.
24. (b) Uchigashima, M.; Narushima, M.; Fukaya, M.; Katona, I.; Kano, M.; Watanabe, M. Subcellular arrangement of molecules for 2-arachidonoylglycerol- mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J. Neurosci. 2007, 27, 3663-3676.
25. (c) Ade, K. K.; Lovinger, D. M. Anandamide regulates postnatal development of long term synaptic plasticity in the rat dorsolateral striatum. J. Neurosci. 2007, 27, 2403-2409.
26. (d) Szabo, B.; Urbanski, M. J.; Bisogno, T.; Di Marzo, V.; Mendiguren, A.; Baer, W. U.; Freiman, I. Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J. Physiol. 2006, 577, 263-280.
27. Blankman, J. L.; Simon, G. M.; Cravatt, B. F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14, 1347-1356.
28. 1 receptor-stimulated cannabinoid CB1 receptor activity. J. Biol. Chem. 2007, 282, 7753-7757.
29. 1 receptor activity in rat brain cryosections by functional autoradiography. J. Neurochem. 2007, 101, 972-981.
30. (a) Kumaraswamy, G.; Markondaiah, B. Enantioselective total synthesis of (-)-tetrahydrolipstatin using Oppolzer's sultam directed aldol reaction. Tetrahedron Lett. 2008, 49, 327-330.
31. (b) Ma, G.; Zancanella, M.; Oyola, Y.; Richardson, R. D.; Smith, J. W.; Romo, D. Total synthesis and comparative analysis of orlistat, valillactone, and a transposed orlistat derivative: inhibitors of fatty acid synthase. Org. Lett. 2006, 8, 4497-4500.
32. (c) Yadav, J. S.; Sridhar Reddy, M.; Prasad, A. R. Stereselective synthesis of (-)-tetrahydrolipstatin via Prins cyclisations. Tetrahedron Lett. 2006, 47, 4995-1998.
33. (d) Yadav, J. S.; Vishweshwar Rao, K.; Prasad, A. R. A chiron approach to (-)-tetrahydrolipstatin. Synthesis 2006, 3888-3894.
34. (e) Yadav, J. S.; Vishweshwar Rao, K.; Sridhar Reddy, M.; Prasad, A. R. Stereoselective synthesis of (-)-tetrahydrolipstatin via a radical cyclization based strategy. Tetrahedron Lett. 2006, 47, 4393-1395.
35. (f) Polkowska, J.; Lukaszewicz, E.; Kiegiel, J.; Jurczak, J. Highly enantioselective hydrogenation of 3,5-diketo esters: a formal synthesis of tetrahydrolipstatin. Tetrahedron Lett. 2004, 45, 3873-3875.
36. (g) Thadani, A. N.; Batey, R. A. Diastereoselective allylations and crotylations under phase-transfer conditions using trifluoroborate salts: an application to the total synthesis of (-)-tetrahydrolipstatin. Tetrahedron Lett. 2003, 44, 8051-8055.
37. (h) Bodkin, J. A.; Humphries, E. J.; McLeod, M. D. The total synthesis of (-)-tetrahydrolipstatin. Tetrahedron Lett. 2003, 44, 2869-2872.
38. (i) Bodkin, J. A.; Humphries, E. J.; McLeod, M. D. The total synthesis of (-)-tetrahydrolipstatin. Aust. J. Chem. 2003, 56, 795-803.
39. (j) Ghosh, A. K.; Fidanze, S. Asymmetric synthesis of (-)-tetrahydrolipstatin: an anti-aldol-based strategy. Org. Lett. 2000, 2, 2405-2407.
40. (k) Parsons, P. J.; Cowell, J. K. A rapid synthesis of (-)-tetrahydrolipstatin. Synlett 2000, 107-109.
41. (l) Wedler, C.; Costisella, B.; Schick, H. Synthesis of enantiomerically pure β-lactones by the tandem aldol-lactonization. A highly efficient access to (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan- 2-one, the key intermediate for the enzyme inhibitors tetrahydrolipstatin and tetrahydroesterastin. J. Org. Chem. 1999, 64, 5301-5303.
42. (m) Paterson, I.; Doughty, V. A. Anti-aldol reactions of lactate-derived ketones. Application to the synthesis of (-)-tetrahydrolipstatin. Tetrahedron Lett. 1999, 40, 393-394.
43. (n) Ghosh, A. K.; Liu, C. A stereoselective synthesis of (-)-tetrahydrolipstatin. Chem. Commun. 1999, 1743-1744.
44. (o) Dirat, O.; Kouklovsky, C.; Langlois, Y. Oxazoline N-oxide-mediated [2 + 3] cycloadditions. Application to a synthesis of (-)-tetrahydrolipstatin. Org. Lett. 1999, 1, 753-755.
45. (p) Fleming, I.; Lawrence, N. J. Stereocontrol in organic synthesis using silicon-containing compounds. A synthesis of (-)-tetrahydrolipstatin using the alkylation of a β-silyl ester and the hydroboration of an allylsilane. J. Chem. Soc., Perkin Trans. 1 1998, 2679-2686.
46. (q) Chadha, N. K.; Batcho, A. D.; Tang, P. C.; Courtney, L. F.; Cook, C. M.; Wovkulich, P. M.; Uskokovich, M. R. Synthesis of tetrahydrolipstatin. J. Org. Chem. 1991, 56, 4714-4718.
47. (r) Barbier, P.; Schneider, F. Synthesis of tetrahydrolipstatin and tetrahydroesterastin, compounds with a β-lactone moiety. Stereoselective hydrogenation of a β-keto δ-lactone and conversion of the δ-lactone into a β-lactone. J. Org. Chem. 1988, 53, 1218-1221.
48. (s) Barbier, P.; Schneider, F.; Widmer, U. Stereoselective syntheses of tetrahydrolipstatin and of an analogue, potent pancreatic-lipase inhibitors containing a β-lactone moiety. Helv. Chim. Acta 1987, 70, 1412-1418.
49. (t) Barbier, P.; Schneider, F. Syntheses of tetrahydrolipstatin and absolute configuration of tetrahydrolipstatin and lipstatin. Helv. Chim. Acta 1987, 70, 196-202.
50. 3 for 2 h, followed by flash chromatography on silica gel using hexane/AcOEt = 7/3 as the eluent (the cost of 84 capsules, each containing 120 mg of THL, is ∼100 Euros).
51. (a) Mullins, J. J. G. Oxetanone derivatives. U.S. Patent 2001012852, 2001.
52. (b) Mullins, J. J. G. Use of oxetanone derivatives as lipase inhibitors. Int. Patent WO 2001032670, 2001.
53. Derungs, R.; Maerki, H. P.; Stalder, H.; Szente, A. Preparation of 4-(acyloxyethyl)oxetan-2-ones. Eur. Patent EP 0444482, 1991.
54. (a) Patel, K.; Kanwar, S.; Deo, K.; Prasad, M. Process for the preparation of orlistat via formylation of amino-orlistat with formic acid anhydride. Int. Patent WO2007039814, 2007.
55. (b) Kumar, Y.; Prasad, M.; Deo, K.; Pandey, A.; Patel, K. Process for preparation of oxetan-2-ones. WO 2005005403, 2005.
56. (c) Watanabe, Y.; Ikemoto, T. Processes for the production of (-)-tetrahydrolipstatin and intermediates thereof. WO 2004065346, 2004.
57. (d) Barbier, P.; Schneider, F.; Widmer. U. Preparation of oxetanones as pancreatic lipase inhibitors. Eur. Patent EP 189577, 1986.
58. (a) Barbier, P.; Schneider, F.; Widmer, U. Preparation of N-formylleucine 1-(oxetanoylmethyl)alkyl esters and analogs as pancreatic lipase inhibitors. U.S. Patent 4931463, 1990.
59. (b) Barbier, P.; Schneider, F.; Widmer, U. Oxetanones. Eur. Patent EP 0185359, 1986.
60. Zhi, J.; Melia, A. T.; Eggers, H.; Joly, R.; Patel, I. H. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J. Clin. Pharmacol. 1995, 35, 1103-1108.